Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Denovo to Acquire Gene Therapy Technology for Oncology from Tocagen

publication date: Apr 28, 2020

Denovo Biopharma, a San Diego-Beijing precision medicine company, announced plans to acquire Tocagen's retroviral replicating vector platform . The assets include Tocagen's investigational gene therapy and drug regimen for oncology: Toca 511 and Toca FC, along with several early-stage candidates, including programs targeting PD-L1 and other immunoncology targets. Denovo develops biomarkers to define patient populations in which abandoned drugs are effective. The company said the Tocagen assets will expand its portfolio while continuing its emphasis on precision medicine. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital